Vaxon Biotech Competitors and Similar CompaniesClear all
Vaxon Biotech's competitors and similar companies include Halozyme Therapeutics, Pharmacyclics, HUYA Bioscience International and Deciphera Pharmaceuticals.
 Halozyme Therapeutics Halozyme Therapeutics is a biotechnology company focused on developing and commercializing cancer therapies that target the tumor microenvironment. |  Pharmacyclics Pharmacyclics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. |  HUYA Bioscience International HUYA Bioscience International is a company specializing in the biopharmaceutical products. |  Deciphera Pharmaceuticals Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company that develops medicines for patients with cancer. | ||
Founding Date | Founding Date 2004 | Founding Date 1998 | Founding Date 1991 | Founding Date 2004 | Founding Date 2003 |
Type | Type Private | Type Public | Type Subsidiary | Type Private | Type Public |
Tags | |||||
Locations | Locations Paris, FR HQ | Locations San Diego, US HQ | Locations Sunnyvale, US HQ | Locations San Diego, US HQ Chengdu Shi, CN Guangzhou Shi, CN Hangzhou, CN Shenzhen Shi, CN Shenzhen Shi, CN Suzhou Shi, CN see more | Locations Waltham, US HQ Lawrence, US |
Employees | Employees N/A | Employees 373157% increase | Employees 6551% decrease | Employees 1113% increase | Employees 35037% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) 6.4 b | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 2.2 b |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $1.4b (FY, 2025) | Revenue (est.) $729.7m (FY, 2014) | Revenue (est.) N/A | Revenue (est.) $163.4m (FY, 2023) |
Cost of goods | Cost of goods N/A | Cost of goods $228.8m (FY, 2025) | Cost of goods $40.4m (FY, 2014) | Cost of goods N/A | Cost of goods $3.7m (FY, 2023) |
Gross profit | Gross profit N/A | Gross profit $1.2b (FY, 2025) | Gross profit $689.3m (FY, 2014) | Gross profit N/A | Gross profit $159.6m (FY, 2023) |
Net income | Net income N/A | Net income $316.9m (FY, 2025) | Net income $86.1m (FY, 2014) | Net income N/A | Net income ($194.9m) (FY, 2023) |
Operating ⚠ | |||||
Patent Applications | Patent Applications N/A | Patent Applications 50 (FY, 2020) | Patent Applications N/A | Patent Applications N/A | Patent Applications 49 (Aug, 2017) |
Patents (US) | Patents (US) N/A | Patents (US) 43 (FY, 2020) | Patents (US) N/A | Patents (US) N/A | Patents (US) 11 (Aug, 2017) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 171.9m | Total funding raised N/A | Total funding raised $ 12.6m | Total funding raised $ 714m |
For sources of this data, please see the company profile
View Company Profiles
Halozyme Therapeutics
HQ
San Diego, US
Employees
373
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing cancer therapies that target the tumor microenvironment.
View companyPharmacyclics
HQ
Sunnyvale, US
Pharmacyclics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases.
View companyHUYA Bioscience International
HQ
San Diego, US
Employees
111↑ 3% increase
HUYA Bioscience International is a company specializing in the biopharmaceutical products.
View companyDeciphera Pharmaceuticals
HQ
Waltham, US
Employees
350↑ 37% increase
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company that develops medicines for patients with cancer.
View company